{"protocolSection": {"identificationModule": {"nctId": "NCT04318093", "orgStudyIdInfo": {"id": "CV019-010"}, "secondaryIdInfos": [{"id": "2019-004186-40", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Bristol-Myers Squibb", "class": "INDUSTRY"}, "briefTitle": "Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure", "officialTitle": "A Randomized, Double-Blinded, Placebo-Controlled, Study to Evaluate the Safety and Tolerability of BMS-986259 in Stabilized Patients Hospitalized for Acute Decompensated Heart Failure"}, "statusModule": {"statusVerifiedDate": "2022-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2020-11-06", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2021-07-19", "type": "ACTUAL"}, "completionDateStruct": {"date": "2021-07-19", "type": "ACTUAL"}, "studyFirstSubmitDate": "2020-03-20", "studyFirstSubmitQcDate": "2020-03-20", "studyFirstPostDateStruct": {"date": "2020-03-23", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2022-07-06", "resultsFirstSubmitQcDate": "2022-08-03", "resultsFirstPostDateStruct": {"date": "2022-08-04", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-08-03", "lastUpdatePostDateStruct": {"date": "2022-08-04", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bristol-Myers Squibb", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of the study is to assess the safety of BMS-986259 in stable participants hospitalized for acute decompensated heart failure."}, "conditionsModule": {"conditions": ["Acute Decompensated Heart Failure"], "keywords": ["Heart failure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 25, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "BMS-986259", "type": "EXPERIMENTAL", "interventionNames": ["Drug: BMS-986259"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "interventionNames": ["Other: Placebo"]}], "interventions": [{"type": "DRUG", "name": "BMS-986259", "description": "Specified dose on specified days", "armGroupLabels": ["BMS-986259"]}, {"type": "OTHER", "name": "Placebo", "description": "Specified dose on specified days", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage of Participants Experiencing Clinically Relevant Hypotension", "description": "Clinically Relevant Hypotension is defined as occurrence of any of the following:\n\n* Supine Systolic Blood Pressure (SBP) \\<85 mmHg (confirmed by repeat measurement within 30 minutes), regardless of symptoms of hypotension\n* Supine SBP \\<90 mmHg (confirmed by repeat measurement within 30 minutes) AND symptoms of hypotension (eg, dizziness, lightheadedness, etc).", "timeFrame": "From first dose to 30 days following first dose"}], "secondaryOutcomes": [{"measure": "Maximum Observed Serum Concentration (Cmax)", "timeFrame": "Day 1 and Day 5 of study treatment"}, {"measure": "Time of Maximum Observed Serum Concentration (Tmax)", "timeFrame": "Day 1 and Day 5 of study treatment"}, {"measure": "Area Under the Concentration-Time Curve Within a Dosing Interval (AUC(TAU))", "timeFrame": "Day 1 and Day 5 of study treatment"}, {"measure": "Trough Concentration (Ctrough)", "timeFrame": "Day 2 through Day 14 of study treatment (with the exception of Day 11, for which data is not available)"}]}, "eligibilityModule": {"eligibilityCriteria": "For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com\n\nInclusion Criteria:\n\n* Participants currently hospitalized for acute decompensated heart failure (ADHF)\n* Participants must be hemodynamically stable, as assessed by the investigator\n* Men must agree to follow specific methods of contraception, if applicable, while participating in the trial\n* Women participants must have documented proof that they are not of childbearing potential\n\nExclusion Criteria:\n\n* Acute cardiovascular condition other than heart failure (HF) decompensation\n* Cardiogenic shock at presentation to emergency room (ER) or at any time before randomization\n* Recipient of ventricular assist devices or use of any cardiac extracorporeal devices, within 12 weeks of study randomization\n* Participants with contraindications to vasodilator therapy such as restrictive or obstructive cardiomyopathy, severe mitral or aortic stenosis\n\nOther protocol-defined inclusion/exclusion criteria apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bristol-Myers Squibb", "affiliation": "Bristol-Myers Squibb", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Local Institution - 0009", "city": "Ciudad de Buenos Aires", "state": "Buenos Aires", "zip": "1180", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Local Institution - 0007", "city": "Alberdi", "state": "Cordoba", "zip": "5000", "country": "Argentina", "geoPoint": {"lat": -32.88987, "lon": -60.69058}}, {"facility": "Local Institution - 0010", "city": "C\u00f3rdoba", "state": "Cordoba", "zip": "X5000EPU", "country": "Argentina", "geoPoint": {"lat": -31.4135, "lon": -64.18105}}, {"facility": "Local Institution", "city": "Ciudad Aut\u00f3noma de Buenos Aires", "state": "Distrito Federal", "zip": "C1093AAS", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Local Institution - 0028", "city": "Cordoba", "state": "Provincia DE Cordoba", "zip": "5000", "country": "Argentina", "geoPoint": {"lat": -31.4135, "lon": -64.18105}}, {"facility": "Local Institution - 0025", "city": "Cordoba", "zip": "5006", "country": "Argentina", "geoPoint": {"lat": -31.4135, "lon": -64.18105}}, {"facility": "Local Institution - 0020", "city": "Praha 2", "zip": "12808", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Nemocnice Slany-Interna - kardiologicka ambulance", "city": "Slany", "zip": "274 01", "country": "Czechia", "geoPoint": {"lat": 50.23046, "lon": 14.08693}}, {"facility": "Local Institution - 0011", "city": "Athens", "zip": "11527", "country": "Greece", "geoPoint": {"lat": 37.97945, "lon": 23.71622}}, {"facility": "Local Institution - 0022", "city": "Athens", "zip": "142 33", "country": "Greece", "geoPoint": {"lat": 37.97945, "lon": 23.71622}}, {"facility": "Local Institution - 0014", "city": "Tel Aviv", "state": "Tell Ab\u012bb", "zip": "6423906", "country": "Israel", "geoPoint": {"lat": 32.08088, "lon": 34.78057}}, {"facility": "Local Institution", "city": "Jerusalem", "zip": "912001", "country": "Israel", "geoPoint": {"lat": 31.76904, "lon": 35.21633}}, {"facility": "Local Institution", "city": "Petah Tikva", "zip": "4941492", "country": "Israel", "geoPoint": {"lat": 32.08707, "lon": 34.88747}}, {"facility": "Local Institution - 0034", "city": "Bialystok", "zip": "15 276", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Local Institution - 0030", "city": "Wrocaw", "zip": "50-556", "country": "Poland"}, {"facility": "Local Institution - 0027", "city": "Wroclaw", "zip": "54-049", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Local Institution", "city": "Edinburgh", "zip": "EH16 4SA", "country": "United Kingdom", "geoPoint": {"lat": 55.95206, "lon": -3.19648}}, {"facility": "Local Institution", "city": "Swindon", "zip": "SN3 6BB", "country": "United Kingdom", "geoPoint": {"lat": 51.55797, "lon": -1.78116}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "BMS Clinical Trial Information", "url": "https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"}, {"label": "BMS Clinical Trial Patient Recruiting", "url": "https://www.bmsstudyconnect.com/s/US/English/USenHome"}, {"label": "FDA Safety Alerts and Recalls", "url": "https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"}, {"label": "Investigator Inquiry Form", "url": "https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "25 participants were randomized and treated.", "groups": [{"id": "FG000", "title": "Placebo", "description": "Placebo matching BMS-986259"}, {"id": "FG001", "title": "BMS-986259 3 mg", "description": "BMS-986259 administered subcutaneously QD for 14 days"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "12"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Participant withdrew consent", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Other reasons", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo", "description": "Placebo matching BMS-986259"}, {"id": "BG001", "title": "BMS-986259 3 mg", "description": "BMS-986259 administered subcutaneously QD for 14 days"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "25"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "10"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "15"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "65.1", "spread": "12.18"}, {"groupId": "BG001", "value": "63.1", "spread": "15.65"}, {"groupId": "BG002", "value": "64.1", "spread": "13.69"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "7"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "18"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "25"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage of Participants Experiencing Clinically Relevant Hypotension", "description": "Clinically Relevant Hypotension is defined as occurrence of any of the following:\n\n* Supine Systolic Blood Pressure (SBP) \\<85 mmHg (confirmed by repeat measurement within 30 minutes), regardless of symptoms of hypotension\n* Supine SBP \\<90 mmHg (confirmed by repeat measurement within 30 minutes) AND symptoms of hypotension (eg, dizziness, lightheadedness, etc).", "populationDescription": "All treated participants", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percent of participants", "timeFrame": "From first dose to 30 days following first dose", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo matching BMS-986259"}, {"id": "OG001", "title": "BMS-986259 3 mg", "description": "BMS-986259 administered subcutaneously QD for 14 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "15.4"}, {"groupId": "OG001", "value": "16.7"}]}]}]}, {"type": "SECONDARY", "title": "Maximum Observed Serum Concentration (Cmax)", "populationDescription": "All participants receiving study drug with available measurements", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng/mL", "timeFrame": "Day 1 and Day 5 of study treatment", "groups": [{"id": "OG000", "title": "BMS-986259 3 mg", "description": "BMS-986259 administered subcutaneously QD for 14 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}]}], "classes": [{"title": "Day 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "105", "spread": "49"}]}]}, {"title": "Day 5", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "268", "spread": "31"}]}]}]}, {"type": "SECONDARY", "title": "Time of Maximum Observed Serum Concentration (Tmax)", "populationDescription": "All participants receiving study drug with available measurements", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Hours", "timeFrame": "Day 1 and Day 5 of study treatment", "groups": [{"id": "OG000", "title": "BMS-986259 3 mg", "description": "BMS-986259 administered subcutaneously QD for 14 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}]}], "classes": [{"title": "Day 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "11.0", "lowerLimit": "7.00", "upperLimit": "23.3"}]}]}, {"title": "Day 5", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "7.97", "lowerLimit": "5.00", "upperLimit": "24.0"}]}]}]}, {"type": "SECONDARY", "title": "Area Under the Concentration-Time Curve Within a Dosing Interval (AUC(TAU))", "populationDescription": "All participants receiving study drug with available measurements", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "h*ng/mL", "timeFrame": "Day 1 and Day 5 of study treatment", "groups": [{"id": "OG000", "title": "BMS-986259 3 mg", "description": "BMS-986259 administered subcutaneously QD for 14 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "classes": [{"title": "Day 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1778", "spread": "40"}]}]}, {"title": "Day 5", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5156", "spread": "36"}]}]}]}, {"type": "SECONDARY", "title": "Trough Concentration (Ctrough)", "populationDescription": "All participants receiving study drug with available measurements", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng/mL", "timeFrame": "Day 2 through Day 14 of study treatment (with the exception of Day 11, for which data is not available)", "groups": [{"id": "OG000", "title": "BMS-986259 3 mg", "description": "BMS-986259 administered subcutaneously QD for 14 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}]}], "classes": [{"title": "Day 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "79.9", "spread": "36.0"}]}]}, {"title": "Day 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "145", "spread": "32.3"}]}]}, {"title": "Day 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "181", "spread": "28.9"}]}]}, {"title": "Day 5", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "185", "spread": "32.4"}]}]}, {"title": "Day 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "210", "spread": "27.3"}]}]}, {"title": "Day 7", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "260", "spread": "41.3"}]}]}, {"title": "Day 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "226", "spread": "69.4"}]}]}, {"title": "Day 9", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "252", "spread": "48.1"}]}]}, {"title": "Day 10", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "259", "spread": "49.7"}]}]}, {"title": "Day 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "229", "spread": "22.9"}]}]}, {"title": "Day 13", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "248", "spread": "50.5"}]}]}, {"title": "Day 14", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "246", "spread": "7.53"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "All-cause mortality was assessed from first dose to study completion date (up to approximately 8 months). SAEs and NSAEs were assessed from first dose to 30 days following first dose.", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Placebo matching BMS-986259", "deathsNumAffected": 2, "deathsNumAtRisk": 13, "seriousNumAffected": 5, "seriousNumAtRisk": 13, "otherNumAffected": 3, "otherNumAtRisk": 13}, {"id": "EG001", "title": "BMS986259 3 mg", "description": "BMS-986259 administered subcutaneously QD for 14 days", "deathsNumAffected": 0, "deathsNumAtRisk": 12, "seriousNumAffected": 2, "seriousNumAtRisk": 12, "otherNumAffected": 8, "otherNumAtRisk": 12}], "seriousEvents": [{"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Cardiac failure chronic", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Cardiogenic shock", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Ventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}]}, {"term": "COVID-19", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}]}, {"term": "COVID-19 pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Acute respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}]}], "otherEvents": [{"term": "Haemoconcentration", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Sinus tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Procedural haemorrhage", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}]}, {"term": "Blood creatinine increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}]}, {"term": "Hypokalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}]}, {"term": "Muscle spasms", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Genital haemorrhage", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 24.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 12}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period \u226460 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication."}, "pointOfContact": {"title": "Bristol-Myers Squibb Study Director", "organization": "Bristol-Myers Squibb", "email": "Clinical.Trials@bms.com", "phone": "Please email"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2020-10-28", "uploadDate": "2022-07-06T16:29", "filename": "Prot_SAP_000.pdf", "size": 1214880}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Netherlands"], "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2022-07-27", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "T170", "name": "Acute Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}}, "hasResults": true}